Literature DB >> 29405252

Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery.

J Vidal Fortuny1, S M Sadowski1, V Belfontali1, S Guigard1, A Poncet2, F Ris3, W Karenovics1, F Triponez1.   

Abstract

BACKGROUND: Hypoparathyroidism, the most common complication after thyroid surgery, leads to hypocalcaemia and significant medical problems. An RCT was undertaken to determine whether intraoperative parathyroid gland angiography with indocyanine green (ICG) could predict postoperative hypoparathyroidism, and obviate the need for systematic blood tests and oral calcium supplementation.
METHODS: Between September 2014 and February 2016, patients who had at least one well perfused parathyroid gland on ICG angiography were randomized to receive standard follow-up (measurement of calcium and parathyroid hormone (PTH) on postoperative day (POD) 1 and systematic supplementation with calcium and vitamin D; control group) or no supplementation and no blood test on POD 1 (intervention group). In all patients, calcium and PTH levels were measured 10-15 days after thyroidectomy. The primary endpoint was hypocalcaemia on POD 10-15.
RESULTS: A total of 196 patients underwent ICG angiography during thyroid surgery, of whom 146 had at least one well perfused parathyroid gland on ICG angiography and were randomized. None of these patients presented with hypoparathyroidism, including those who did not receive calcium supplementation. The intervention group was statistically non-inferior to the control group (exact 95 per cent c.i. of the difference in proportion of patients with hypocalcaemia -0·053 to 0·053; P = 0·012). Eleven of the 50 excluded patients, in whom no well perfused parathyroid gland could be identified by angiography, presented with hypoparathyroidism on POD 1, and six on POD 10-15, which was significantly different from the findings in randomized patients (P = 0·007).
CONCLUSION: ICG angiography reliably predicts the vascularization of the parathyroid glands and obviates the need for postoperative measurement of calcium and PTH, and supplementation with calcium in patients with at least one well perfused parathyroid gland. Registration number: NCT02249780 (http://www.clinicaltrials.gov).
© 2018 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29405252      PMCID: PMC6084300          DOI: 10.1002/bjs.10783

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


Introduction

Temporary hypoparathyroidism leading to hypocalcaemia is the most common complication after total thyroidectomy. Depending on the technical difficulty of the procedure and expertise of the surgeon, this is seen in up to 30 per cent of patients undergoing total thyroidectomy1, 2. Permanent hypocalcaemia, defined as hypocalcaemia present for more than 6 months after thyroidectomy, is reported in 1–10 per cent of patients3, 4. Minimizing hypoparathyroidism is important for quality of life, as postoperative hypocalcaemia may result in prolonged admission to hospital and multiple clinic visits, neuromuscular symptoms, the need for lifelong calcium and vitamin D supplementation, and long‐term complications5, 6. Preservation of the parathyroid glands can be challenging, as normal postoperative parathyroid function is not guaranteed even when the parathyroid glands appear to be well preserved during surgery. For more than a century, systematic postoperative measurement of calcium and/or parathyroid hormone (PTH) levels, and/or systematic supplementation with calcium and vitamin D therapy have been common standard management after total thyroidectomy7, 8, 9. Although capsular dissection techniques and preservation of the surrounding vasculature are used to avoid inadvertent parathyroidectomy or disruption of the parathyroid vasculature10, 11, reliable tools to both identify and assess parathyroid glands during surgery, and to predict whether a patient will develop hypoparathyroidism, are limited3, 12, 13. Current methods are based on measurement of calcium14, 15 and PTH4, 16, 17, 18, 19, 20 levels at different time points, with early (a few minutes to 12 h after thyroid resection) PTH measurements reliably predicting the absence of hypoparathyroidism4, 16, 17. Other authors18, 21, 22 have suggested using quick PTH measurements, which could also help the surgeon decide whether or not to autotransplant a parathyroid gland. In addition, viability scores, based on visual evaluation of the parathyroid glands, have been used to predict postoperative hypoparathyroidism23. The study by Ji and colleagues23, however, also clearly demonstrated that visual scores are not reliable because, of 111 patients with a global score indicating that at least one parathyroid gland was classified visually as normal, 12 (10·8 per cent) had hypoparathyroidism on postoperative day (POD) 1. Recently, near‐infrared fluorescence imaging has renewed interest in intraoperative parathyroid imaging. Initially used in the detection of macular degeneration24, the technique of angiography using indocyanine green (ICG) has also been used to determine the extent of oncological resection25, to study hepatic function26 and to evaluate blood flow in intestinal anastomoses27. Vidal Fortuny and colleagues28, 29 previously reported an initial experience of using ICG to evaluate intraoperative perfusion of parathyroid glands in predicting parathyroid function after thyroidectomy and subtotal parathyroidectomy. These studies demonstrated that having one well perfused parathyroid gland/parathyroid gland remnant was sufficient to avoid hypoparathyroidism. Another study30 reported similar findings in 23 patients undergoing thyroidectomy. The aim of the present RCT was to determine whether systematic measurement of calcium and PTH, and systematic supplementation of calcium and vitamin D therapy can be omitted in patients with at least one well perfused parathyroid gland identified by ICG angiography after thyroidectomy.

Methods

The study enrolled patients from September 2014 until February 2016, and was approved by the Ethics Review Board of the University Hospitals of Geneva (HUG 08‐2014). The trial was registered at http://clinicaltrials.gov (NCT02249780). Written informed consent was obtained from all study participants. Thyroid surgery was performed by three experienced surgeons, using a standard protocol. The recurrent laryngeal nerve was identified during the procedure using neural monitoring (NIM 3.0®; Medtronic, Dublin, Ireland). No systematic search for parathyroid glands during total thyroidectomy was done and the dissection was performed close to the thyroid gland. Once the thyroid specimen had been removed, it was actively searched for parathyroid glands, which were then prepared for reimplantation if needed. The number of parathyroid glands identified in each patient was recorded. After the thyroid gland had been removed, intraoperative angiography was performed on the identified parathyroid glands using a near‐infrared camera (Pinpoint®; Novadaq, Toronto, Ontario, Canada). ICG (2·5 mg/ml) was prepared as described previously and injected intravenously29, 31. Repeated doses were allowed until a maximum toxic dose of 5 mg/kg was reached. Approximately 1–2 min later, images were acquired by the near‐infrared system and recorded. Each identified parathyroid gland was classified according to the degree of ICG fluorescence: ICG score 0, a black parathyroid gland after the injection of ICG, indicating a non‐vascularized gland; ICG score 1, a grey or heterogeneous parathyroid gland, suggesting that the gland is partially vascularized; or ICG score 2, a white parathyroid gland, indicating that the gland is well vascularized (Fig. 1)29, 31. If there was discordance between surgeons in evaluating ICG fluorescence, the lowest value was taken into account.
Figure 1

Representative images of a devascularized (indocyanine green (ICG) score 0), b moderately well vascularized (ICG score 1) and c well vascularized (ICG score 2) parathyroid gland assessed using ICG angiography (Video  S1, supporting information). Circles indicate the parathyroid gland

Representative images of a devascularized (indocyanine green (ICG) score 0), b moderately well vascularized (ICG score 1) and c well vascularized (ICG score 2) parathyroid gland assessed using ICG angiography (Video  S1, supporting information). Circles indicate the parathyroid gland Patients with at least one well perfused parathyroid gland (ICG score 2) were considered eligible for randomization. Study inclusion criteria were: adult patients undergoing total thyroidectomy or completion thyroidectomy with an ICG score of 2 in at least one identified parathyroid gland, and a signed informed consent. Exclusion criteria were: concurrent parathyroid disease or combined surgery (thyroidectomy and parathyroidectomy); ICG score below 2 for all identified parathyroid glands; postoperative bleeding requiring reintervention; lack of informed consent; and altered mental status. Randomization was performed by the surgical team after ICG angiography at the end of the surgical procedure, by opening a sealed envelope.

Follow‐up

Patients in the control group had standard follow‐up consisting of measurement of calcium and PTH levels on POD 1 and POD 10–15, and systematic oral supplementation with 1 g calcium and 800 units 25‐hydroxyvitamin D twice daily until the first follow‐up appointment (POD 10–15). Patients in the intervention group had postoperative clinical follow‐up comprising assessment for symptoms of hypocalcaemia, but no blood tests to determine calcium or PTH levels on POD 1, and no oral calcium and vitamin D supplementation. Calcium and PTH levels were measured on POD 10–15 to confirm that levels were normal. When symptoms of hypocalcaemia developed during the hospital stay, calcium and PTH levels were measured, and supplementation was started (or increased in the control group) until symptoms resolved, without waiting for the results. At discharge, patients were taught to look for hypocalcaemia‐related symptoms and advised to contact the surgical team if symptoms occurred.

Laboratory measurements

The Central Clinical Laboratory of the University Hospitals of Geneva performed all blood analyses. Calcium levels were adjusted according to serum albumin (calciumcorrected = + calciummeasured). The normal range at the authors' institution was 1·1–6·8 pmol/l for PTH and 2·20–2·52 mmol/l for calcium. Hypocalcaemia was defined by a corrected calcium level of less than 2·00 mmol/l and hypoparathyroidism by a PTH level lower than 1·1 pmol/l.

Statistical analysis

Because the study aimed to provide proof of concept, a large non‐inferiority margin of 7 per cent was adopted, in order to show the safety of stopping blood tests and calcium supplementation without hypocalcaemic episodes. Using exact methods and assuming an expected proportion of failure of 1·5 per cent in both groups, 69 patients per group were needed to obtain a power of at least 80 per cent (calculation performed in StatXact‐4 (Cytel, Cambridge, Massachusetts, USA) using a 1‐sided test with a type I error risk (α) of 0·025). All results were recorded in a secure database to which only the principal investigator had access; recorded images were stocked for analysis. Continuous data are presented as mean(s.d.), and categorical variables as frequencies and percentages. The main binary outcome (presence or absence of hypocalcaemia on POD 10) was compared between the two groups using an unconditional exact test of non‐inferiority for two independent binomial samples, to assess whether the intervention group was non‐inferior to the control group. Paired t test was used to compare the calcium and PTH values on POD 1 and POD 10. Statistical significance was assessed at the two‐sided 0·05 level for all analyses. All analyses were performed using R software (R Foundation for Statistical Computing, Vienna, Austria), except the exact test of non‐inferiority, which was undertaken using StatXact® version 11 software.

Results

Between September 2014 and February 2016, 196 patients underwent ICG angiography during total thyroidectomy or completion thyroidectomy, and a total of 499 parathyroid glands were evaluated (mean(s.d.) 2·5(1·0) parathyroid glands per patient) (Table 1). Of the 146 patients who met the inclusion criteria (at least 1 parathyroid gland with an ICG score of 2), 73 were randomized to the intervention group and 73 to the control group (Fig. 2).
Table 1

Number of parathyroid glands evaluated in each patient

No. of glands evaluatedControl group (n = 73)Intervention group (n = 73)Excluded group* (n = 50)Total (n = 196)
11381435 (17·9)
221241964 (32·7)
31925852 (26·5)
42016945 (23·0)

Values in parentheses are percentages.

Patients were excluded from the study before randomization if indocyanine green (ICG) angiography showed none of the parathyroid glands to have an ICG score of 2.

Figure 2

CONSORT diagram showing randomization and allocation of the study cohort. POD, postoperative day

Number of parathyroid glands evaluated in each patient Values in parentheses are percentages. Patients were excluded from the study before randomization if indocyanine green (ICG) angiography showed none of the parathyroid glands to have an ICG score of 2. CONSORT diagram showing randomization and allocation of the study cohort. POD, postoperative day The intervention and control groups did not differ with respect to surgical diagnosis and extent of surgery (Table 2). Fifty patients in whom ICG angiography failed to demonstrate at least one well perfused parathyroid gland were excluded from the randomized part of the study, but did not otherwise differ from included patients with respect to surgical diagnosis, surgical procedure, findings at pathology or other demographic characteristics (Table 2).
Table 2

Demographic and clinical characteristics

Control group (n = 73) Intervention group (n = 73) Excluded group (n = 50)
Age (years)* 50·9(15·4)53·9(15·9)50·6(12·1)
Sex ratio (M : F)11 : 6211 : 6217 : 33
ASA score* 1·91(0·43)1·95(0·45)1·90(0·46)
Indication for surgery
Multinodular goitre41 (56)33 (45)30 (60)
Thyroid cancer17 (23)30 (41)15 (30)
Graves' disease15 (21)10 (14)5 (10)
Extent of surgery
Completion thyroidectomy5 (7)11 (15)5 (10)
Total thyroidectomy59 (81)45 (62)37 (74)
Total thyroidectomy + central neck dissection6 (8)15 (21)2 (4)
Total thyroidectomy + central + lateral neck dissection3 (4)2 (3)6 (12)
Duration of hospital stay (days)* 1·53(1·15)1·48(0·98)1·38(0·69)

Values in parentheses are percentages unless indicated otherwise;

values are mean(s.d.).

Patients were excluded from the study before randomization if indocyanine green (ICG) angiography showed none of the parathyroid glands to have an ICG score of 2.

Demographic and clinical characteristics Values in parentheses are percentages unless indicated otherwise; values are mean(s.d.). Patients were excluded from the study before randomization if indocyanine green (ICG) angiography showed none of the parathyroid glands to have an ICG score of 2.

Randomized patients

Hypocalcaemia (calcium level below 2·00 mmol/l) was not observed in either group. The intervention group was statistically non‐inferior to the control group as the higher boundary of the confidence interval of the difference in hypocalcaemia proportion was lower than 0·07 (exact 95 per cent c.i. of difference –0·053 to 0·053; P = 0·012). There was no difference in calcium or PTH levels between the groups on POD 10 (Table 3). No hypoparathyroidism (PTH level less than 1·1 pmol/l) was observed in either group.
Table 3

Comparison of calcium and parathyroid levels between the randomized groups

Control group (n = 73) Intervention group (n = 73)Difference P §
Calcium (mmol/l)*
POD 12·27(0·10)n.a.
POD 102·31(0·10) 2·30(0·11)0·012 (–0·022, 0·046)0·480
PTH (pmol/l)*
POD 13·28(1·39)n.a.
POD 104·44(2·19) 4·88(2·05)–0·441 (–1·144, 0·262)0·217

Values are mean(s.d.);

values in parentheses are 95 per cent confidence intervals.

Calcium and parathyroid hormone (PTH) levels were significantly higher on POD 10 than POD 1 in the control group (mean difference in calcium 0·039 (95 per cent c.i. 0·012 to 0·067) mmol/l, P = 0·006; mean difference in PTH 1·13 (0·66 to 1·61) pmol/l, P < 0·001). POD, postoperative day; n.a., not available.

Paired t test.

Comparison of calcium and parathyroid levels between the randomized groups Values are mean(s.d.); values in parentheses are 95 per cent confidence intervals. Calcium and parathyroid hormone (PTH) levels were significantly higher on POD 10 than POD 1 in the control group (mean difference in calcium 0·039 (95 per cent c.i. 0·012 to 0·067) mmol/l, P = 0·006; mean difference in PTH 1·13 (0·66 to 1·61) pmol/l, P < 0·001). POD, postoperative day; n.a., not available. Paired t test. As completion thyroidectomy can be considered a confounding factor, with the parathyroid glands on the side operated first having more time to recover, the data were reanalysed after exclusion of 16 patients who underwent completion thyroidectomy (11 in the intervention group and 5 in the control group). This did not change the result of non‐inferiority of the intervention (exact 95 per cent c.i. of difference –0·062 to 0·062; P = 0·020). Two patients in the intervention group experienced typical symptoms of hypocalcaemia but had PTH levels in the normal range on POD 10, without calcium supplementation. One had a calcium level of 2·05 mmol/l, PTH level of 3·7 pmol/l and mild finger paraesthesia, which rapidly improved after oral calcium supplementation (dose 1 g). The other patient also experienced finger paraesthesia, with calcium and PTH values of 2·29 mmol/l and 5·2 pmol/l respectively. The symptoms improved a few minutes after oral calcium supplementation (1 g). For patients in the control group, standard oral supplementation kept calcium levels within normal limits; higher doses or additional active vitamin D were never needed.

Non‐randomized patients

ICG angiography failed to demonstrate at least one well perfused parathyroid gland in 50 patients, who were therefore not included in the randomized part of the study. Eleven of the 50 patients presented with hypoparathyroidism on POD 1, and six on POD 10; this was significantly different from the findings in randomized patients (P = 0·007). Two of the 11 patients presented with symptomatic hypocalcaemia, despite systematic calcium supplementation, and needed intravenous calcium supplementation for 24 h. One patient still had hypoparathyroidism at 6 months; the other patient had normal calcium and PTH levels without calcium supplements at 6 months.

Discussion

This RCT studied the value of ICG angiography of the parathyroid glands during thyroid surgery in predicting postoperative hypoparathyroidism. The findings indicate that ICG angiography is a good predictor of the absence of hypoparathyroidism after thyroidectomy, in contrast to visual evaluation of the parathyroid glands23, 32, 33. In this consecutive series of 196 patients, a well vascularized parathyroid gland could be identified in 146 (74·5 per cent) and none of the subsequently randomized patients presented with hypocalcaemia. Therefore, calcium and/or PTH measurements may no longer be necessary in patients with at least one well perfused parathyroid gland, as demonstrated by ICG angiography after thyroidectomy. Postoperative hypoparathyroidism is the most common complication of total thyroidectomy3, and patients are at risk of developing permanent hypoparathyroidism. In severe cases this can lead to cerebral, vascular, ocular and renal damage, and to a significant reduction in quality of life6, 34, 35, 36. For more than a century, hypocalcaemia symptoms have been monitored carefully and measurements of calcium (and often PTH) levels used as standard of care after total thyroidectomy. Unlike ICG angiography, none of the currently used methods (serial calcium measurements14, PTH measurement a few hours after thyroidectomy9, 37 or even intraoperative PTH measurements19, 20) can predict the absence of hypoparathyroidism immediately after thyroid resection. Most thyroid centres use a combination of postoperative calcium and/or PTH measurements, with calcium (and sometimes vitamin D) supplementation given either systematically to prevent symptomatic hypocalcaemia, or on demand according to calcium level and/or symptoms. The protocol differs between centres, mainly depending on the length of hospital stay, the prevalence of hypocalcaemia and the personal preferences of each surgeon3, 4. Before the present study, the standard protocol at the authors' institution included determination of corrected calcium level and PTH on POD 1, and systematic supplementation with calcium and 25‐hydroxyvitamin D. ICG fluorescence is one of the most recent breakthroughs in the field of intraoperative imaging and, as the present results show, modifies perioperative surgical management. First, it might prevent hypoparathyroidism by limiting trauma to the parathyroid glands during surgery, with the surgeon dissecting the parathyroid gland vasculature more thoroughly and carefully, and eventually leaving a thyroid remnant to preserve the parathyroid glands11. Second, ICG fluorescence allows each gland to be evaluated separately, and does not limit evaluation to overall parathyroid gland function. Another advantage of ICG fluorescence is the change in management of parathyroid glands to be reimplanted. In this study, 37 parathyroid glands were autotransplanted in 34 patients; 14 could not be preserved in situ or were found in the specimen after resection, and 23 were autotransplanted based on ICG results indicating absence of perfusion. A difficulty with ICG angiography is identifying parathyroid glands with certainty. Even experienced thyroid surgeons might misinterpret other anatomical structures for a parathyroid gland. In experienced hands, however, the rate of correct identification of a structure as a parathyroid gland should exceed 95 per cent38, and the results of the present study also suggest that a systematic biopsy is not necessary to confirm that the structure identified is indeed a parathyroid gland. In less experienced hands, it would be valuable to have a tool to help detect and identify parathyroid glands. New reports on parathyroid gland autofluorescence39, 40 envisage use of a combination of autofluorescence to identify the parathyroid glands, followed by ICG angiography to confirm their vascularization. However, the equipment used in the present study cannot currently detect parathyroid gland autofluorescence, as it is unable to stimulate and detect a precise wavelength. Because all four parathyroid glands were not identified, which is not unusual in standard thyroidectomy, the vascularization and function of the unidentified parathyroid glands remain unknown. Consequently, a direct correlation between ICG scores (of individual parathyroid glands) and PTH levels could not be shown in this study. In another study31 of patients undergoing subtotal parathyroidectomy, the ICG score of the parathyroid remnant correlated with postoperative function, and thus PTH secretion could be attributed directly to the parathyroid remnant. Another limitation is the subjective nature of visual and ICG scores. Fluorescence was not quantifiable with the fluorescence equipment used; instead, shades of grey of the parathyroid gland were compared visually with those of the surrounding vessels and tissues41. Unfortunately, the Novadaq camera system used in this study does not give a quantitative/numerical score but a qualitative one, in colour shades. Other options, such as pixel/colour analysing computer programs, could be used in the future to score the angiography results objectively. The randomized design should, however, reduce the bias of non‐quantifiable fluorescence to a minimum. The follow‐up of 10–15 days appeared sufficient for assessing both immediate postoperative parathyroid function and the absence of long‐term/delayed hypoparathyroidism as patients with good postoperative function will not develop late hypoparathyroidism. This prospective RCT has demonstrated that finding one well perfused parathyroid gland using ICG angiography is a reliable way of predicting the absence of postoperative hypoparathyroidism. Total thyroidectomy can be performed safely without systematic calcium/PTH measurement, without systematic calcium supplementation, and with no risk of hypocalcaemia in patients with at least one well vascularized parathyroid gland. The use of this tool could contribute to the development of same day/ambulatory surgery. The next step is to use ICG angiography to not only predict but also prevent post‐thyroidectomy hypoparathyroidism. Because of its unique ability to guarantee the function of individual parathyroid glands31, ICG angiography can be performed after the first lobe of the thyroid has been resected, and the extent of resection of the second side of the thyroid can be adapted accordingly; a near‐total or subtotal thyroidectomy can be performed for the second side for benign thyroid disease (and even for low‐grade thyroid cancer, according to recent recommendations42) if ICG angiography cannot demonstrate a well vascularized parathyroid gland after resection of the first side. This future area of research could significantly help decrease the rate of postoperative hypoparathyroidism. Video (a): The video shows ICG angiography after total thyroidectomy. The first evaluated parathyroid gland is the right inferior and it is well vascularized (at about 1'00”) The second evaluated PG is the right superior and is moderately well vascularized (at about 1'39”) The third evaluated PG is the left inferior and is not vascularized (ICG score of 0) at about 2'30” and the pictures a, a' and a” were taken from this PG. The fourth evaluated PG is the left superior and is not vascularized, at about 3'06” Click here for additional data file. Video (b): The video shows ICG angiography after total thyroidectomy, but only the 2 left PGs are shown in the video: The first evaluated PG is the left inferior at about 0'15”, and despite the fact that vessels around the PG show a very good perfusion, the PG itself is surprisingly only moderately well vascularized (ICG score of 1). The pictures (b, b' and b”) were taken from this PG. The second evaluated PG is the left superior and is well‐vascularized at 43” Click here for additional data file. Video (c): the video shows ICG angiography after total thyroidectomy. Only part of the first evaluated PG, the right superior (at about 0'45”) is well vascularized. The left superior (at 3'30”) is well vascularized (ICG score of 2) and pictures c, c' and c” were taken from this PG. Click here for additional data file.
  41 in total

1.  Parathyroid biopsy to facilitate the preservation of functional parathyroid tissue during thyroidectomy.

Authors:  W I Kuhel; J F Carew
Journal:  Head Neck       Date:  1999-08       Impact factor: 3.147

2.  Routine parathyroid autotransplantation during thyroidectomy.

Authors:  C Y Lo; K Y Lam
Journal:  Surgery       Date:  2001-03       Impact factor: 3.982

3.  Near infra-red laparoscopic assessment of the adequacy of blood perfusion of intestinal anastomosis - a video vignette.

Authors:  F Ris; R Hompes; I Lindsey; C Cunningham; N J Mortensen; R A Cahill
Journal:  Colorectal Dis       Date:  2014-08       Impact factor: 3.788

4.  Indocyanine Green Angiography in Subtotal Parathyroidectomy: Technique for the Function of the Parathyroid Remnant.

Authors:  Jordi Vidal Fortuny; Samira M Sadowski; Valentina Belfontali; Wolfram Karenovics; Sebastien Guigard; Frederic Triponez
Journal:  J Am Coll Surg       Date:  2016-08-24       Impact factor: 6.113

5.  Parathyroid hormone levels 4 hours after surgery do not accurately predict post-thyroidectomy hypocalcemia.

Authors:  Celestino Pio Lombardi; Marco Raffaelli; Pietro Princi; Chiara Dobrinja; Cinzia Carrozza; Enrico Di Stasio; Annamaria D'Amore; Cecilia Zuppi; Rocco Bellantone
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

6.  Prediction of permanent hypoparathyroidism after total thyroidectomy.

Authors:  M Almquist; P Hallgrimsson; E Nordenström; A Bergenfelz
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

7.  American Thyroid Association statement on outpatient thyroidectomy.

Authors:  David J Terris; Samuel Snyder; Denise Carneiro-Pla; William B Inabnet; Emad Kandil; Lisa Orloff; Maisie Shindo; Ralph P Tufano; R Michael Tuttle; Mark Urken; Michael W Yeh
Journal:  Thyroid       Date:  2013-09-14       Impact factor: 6.568

8.  Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D.

Authors:  Wiebke Arlt; Christian Fremerey; Frank Callies; Martin Reincke; Peter Schneider; Wolfgang Timmermann; Bruno Allolio
Journal:  Eur J Endocrinol       Date:  2002-02       Impact factor: 6.664

9.  Is therapy with calcium and vitamin D and parathyroid autotransplantation useful in total thyroidectomy for preventing hypocalcemia?

Authors:  Bassam Abboud; Ghassan Sleilaty; Salam Zeineddine; Carla Braidy; Rony Aouad; Cyril Tohme; Roger Noun; Riad Sarkis
Journal:  Head Neck       Date:  2008-09       Impact factor: 3.147

10.  A prospective evaluation of quick intraoperative parathyroid hormone assay at the time of skin closure in predicting clinically relevant hypocalcemia after thyroidectomy.

Authors:  Brian Hung-Hin Lang; Patricia Chun-Ling Yih; Ka Kin Ng
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

View more
  37 in total

1.  Re: Evaluation of Parathyroid Glands with Indocyanine Green Fluorescence Angiography After Thyroidectomy.

Authors:  Frédéric Triponez
Journal:  World J Surg       Date:  2019-06       Impact factor: 3.352

2.  Indocyanine green fluorescence imaging during partial adrenalectomy.

Authors:  Maximilian Lerchenberger; Ufuk Gündogar; Norah Al Arabi; Julia K S Gallwas; Herbert Stepp; Klaus K J Hallfeldt; Roland Ladurner
Journal:  Surg Endosc       Date:  2019-07-24       Impact factor: 4.584

Review 3.  Morbidity following thyroid surgery: acceptable rates and how to manage complicated patients.

Authors:  M N Minuto; S Reina; E Monti; G L Ansaldo; E Varaldo
Journal:  J Endocrinol Invest       Date:  2019-05-23       Impact factor: 4.256

4.  Hypocalcemia after Total Thyroidectomy in Graves Disease.

Authors:  Malak Al Qubaisi; Philip I Haigh
Journal:  Perm J       Date:  2019-05-17

5.  Does fluoroscopy prevent inadvertent parathyroidectomy in thyroid surgery?

Authors:  A DiMarco; R Chotalia; R Bloxham; C McIntyre; N Tolley; F F Palazzo
Journal:  Ann R Coll Surg Engl       Date:  2019-07-15       Impact factor: 1.891

6.  Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials.

Authors:  Behnood Bikdeli; César Caraballo; John Welsh; Joseph S Ross; Sanjay Kaul; Gregg W Stone; Harlan M Krumholz
Journal:  Clin Trials       Date:  2020-08-24       Impact factor: 2.486

Review 7.  Intraoperative Indocyanine Green (ICG) Angiography for the Identification of the Parathyroid Glands: Current Evidence and Future Perspectives.

Authors:  Eleftherios Spartalis; Georgios Ntokos; Konstantinos Georgiou; Georgios Zografos; Gerasimos Tsourouflis; Dimitrios Dimitroulis; Nikolaos I Nikiteas
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 8.  Application of Fluorescent Dyes in Visceral Surgery: State of the Art and Future Perspectives.

Authors:  Kai Nowak; Ioannis Karampinis; Andreas Lutz Heinrich Gerken
Journal:  Visc Med       Date:  2020-03-26

9.  Current state of intraoperative use of near infrared fluorescence for parathyroid identification and preservation.

Authors:  Carmen C Solórzano; Giju Thomas; Eren Berber; Tracy S Wang; Gregory W Randolph; Quan-Yang Duh; Frédéric Triponez
Journal:  Surgery       Date:  2020-11-01       Impact factor: 3.982

10.  The utility of indocyanine green (ICG) for the identification and assessment of viability of the parathyroid glands during thyroidectomy.

Authors:  S Priyanka; Shawn Thomas Sam; Grace Rebekah; Supriya Sen; Varghese Thomas; Syrpailyne Wankhar; Anish Jacob Cherian; Deepak Thomas Abraham; Mazuvanchary Jacob Paul
Journal:  Updates Surg       Date:  2021-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.